Search results
The doctor behind the next big thing in cancer treatment
CNN via Yahoo News· 5 days agoDr Catherine Wu’s research has laid the scientific foundation for the development of cancer vaccines...
MemorialCare Cancer Institute Revolutionizes Prostate Cancer Treatment: Hot Water Potential Solution...
WFRV 5 Green Bay· 7 days agoMemorialCare Cancer Institute at Saddleback Medical Center is the only location in Orange County – and one of only two in California – to offer a new, innovative way to treat prostate cancer ...
Commit Biologics advances complement platform with €16m seed financing
BioPharma-Reporter· 5 days agoThe Danish biotech is pioneering a novel approach to activating the complement component of the...
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 16 hours agoFate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript May 11, 2024 Fate...
The Webb Space Telescope found a nearby planet with an atmosphere
Quartz· 5 days agoScientists have spotted a rocky exoplanet with a possible atmosphere, which they believe may be...
Tumors cells with mismatch repair deficiency induce hyperactivation of pyroptosis resistant to cell...
Nature· 24 hours agoHypermutated neoantigens in cancers with DNA mismatch repair deficiency (dMMR) are prerequisites for favorable clinical responses to immune-checkpoint blockade (ICB) therapy. However, TMB is ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 29 minutes agoDelhi, May 14, 2024 (GLOBE NEWSWIRE) -- Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030 Report Highlights: Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1.50 Billion By 2030Oncolytic
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via Yahoo News· 20 hours agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target Increased to $60.00 by Analysts at Oppenheimer
ETF DAILY NEWS· 4 days agoCorbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) had its target price upped by equities research analysts at Oppenheimer from $58.00 to $60.00 in a research report issued to clients and ...
UK’s leading lab supplier launches investigation into N-word slurs on products
The Independent via Yahoo News· 6 days agoThe UK’s largest independent supplier of laboratory materials has removed an N-word racist slur...